Literature DB >> 29229668

Multiple Myeloma and Bone: The Fatal Interaction.

Silvia Marino1, G David Roodman1,2.   

Abstract

Multiple myeloma (MM) is the second-most-common hematologic malignancy and the most frequent cancer to involve bone. MM bone disease (MMBD) has devastating consequences for patients, including dramatic bone loss, severe bone pain, and pathological fractures that markedly decrease the quality of life and impact survival of MM patients. MMBD results from excessive osteoclastic bone resorption and persistent suppressed osteoblastic bone formation, causing lytic lesions that do not heal, even when patients are in complete and prolonged remission. This review discusses the cellular and molecular mechanisms that regulate the uncoupling of bone remodeling in MM, the effects of MMBD on tumor growth, and potential therapeutic approaches that may prevent severe bone loss and repair damaged bone in MM patients.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29229668      PMCID: PMC6071546          DOI: 10.1101/cshperspect.a031286

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  193 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

Authors:  William G Gunn; Adam Conley; Lisa Deininger; Scott D Olson; Darwin J Prockop; Carl A Gregory
Journal:  Stem Cells       Date:  2005-11-17       Impact factor: 6.277

3.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

4.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

Authors:  Michel Delforge; Evangelos Terpos; Paul G Richardson; Ofer Shpilberg; Nuriet K Khuageva; Rudolf Schlag; Meletios A Dimopoulos; Martin Kropff; Ivan Spicka; Maria T Petrucci; Olga S Samoilova; Maria-Victoria Mateos; Hila Magen-Nativ; Hartmut Goldschmidt; Dixie-Lee Esseltine; Deborah S Ricci; Kevin Liu; William Deraedt; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
Journal:  Eur J Haematol       Date:  2011-03-30       Impact factor: 2.997

6.  IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

Authors:  Lori A Ehrlich; Ho Yeon Chung; Irene Ghobrial; Sun Jin Choi; Francesca Morandi; Simona Colla; Vittorio Rizzoli; G David Roodman; Nicola Giuliani
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

7.  Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

Authors:  Fred Saad; Allan Lipton; Richard Cook; Yin-Miao Chen; Matthew Smith; Robert Coleman
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

8.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

9.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

10.  Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.

Authors:  Anup Kasi Loknath Kumar; Christopher Dakhil; Megha Teeka Satyan; Nisreen Haideri
Journal:  J Med Case Rep       Date:  2014-09-08
View more
  12 in total

Review 1.  Regulation of Energy Metabolism by Bone-Derived Hormones.

Authors:  Paula Mera; Mathieu Ferron; Ioanna Mosialou
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

2.  HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia.

Authors:  Jingyu Xiang; Daniel A Rauch; Devra D Huey; Amanda R Panfil; Xiaogang Cheng; Alison K Esser; Xinming Su; John C Harding; Yalin Xu; Gregory C Fox; Francesca Fontana; Takayuki Kobayashi; Junyi Su; Hemalatha Sundaramoorthi; Wing Hing Wong; Yizhen Jia; Thomas J Rosol; Deborah J Veis; Patrick L Green; Stefan Niewiesk; Lee Ratner; Katherine N Weilbaecher
Journal:  JCI Insight       Date:  2019-10-03

Review 3.  Acupuncture for Cancer-Induced Bone Pain in Animal Models: A Systemic Review and Meta-Analysis.

Authors:  Mei-Ling Yu; Jia-Jia Qian; Shu-Ping Fu; Jia-Ying Chen; Yu-Wen Zheng; Zhi-Gang Lu; Sheng-Feng Lu
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-30       Impact factor: 2.629

4.  Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.

Authors:  Fumou Sun; Yan Cheng; Susan A Walsh; Michael R Acevedo; Xuefang Jing; Seong Su Han; Michael D Pisano; Michael H Tomasson; Alan K Lichtenstein; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

Review 5.  Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts.

Authors:  Alison B Shupp; Alexus D Kolb; Dimpi Mukhopadhyay; Karen M Bussard
Journal:  Cancers (Basel)       Date:  2018-06-04       Impact factor: 6.639

Review 6.  The Regulation of Bone Metabolism and Disorders by Wnt Signaling.

Authors:  Kazuhiro Maeda; Yasuhiro Kobayashi; Masanori Koide; Shunsuke Uehara; Masanori Okamoto; Akihiro Ishihara; Tomohiro Kayama; Mitsuru Saito; Keishi Marumo
Journal:  Int J Mol Sci       Date:  2019-11-06       Impact factor: 5.923

7.  Assessment of Bone Health Education in US Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events.

Authors:  Darcy R Flora; Katherine B Carlson; David C Fuehrer; Benoit Cadieux; Guy Boike; Jennifer Schenfeld; Kimberly A Lowe
Journal:  Cancer Manag Res       Date:  2021-04-23       Impact factor: 3.989

Review 8.  Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.

Authors:  Benoit Cadieux; Robert Coleman; Pegah Jafarinasabian; Allan Lipton; Robert Z Orlowski; Fred Saad; Giorgio V Scagliotti; Kazuyuki Shimizu; Alison Stopeck
Journal:  J Bone Oncol       Date:  2022-02-07       Impact factor: 4.072

9.  Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes.

Authors:  Konstantin Byrgazov; Thomas Lind; Annica J Rasmusson; Claes Andersson; Ana Slipicevic; Fredrik Lehmann; Joachim Gullbo; Håkan Melhus; Rolf Larsson; Mårten Fryknäs
Journal:  Bone Rep       Date:  2021-06-07

10.  Human P2X7 Receptor Causes Cycle Arrest in RPMI-8226 Myeloma Cells to Alter the Interaction with Osteoblasts and Osteoclasts.

Authors:  Ankita Agrawal; Lars S Kruse; Annette J Vangsted; Alison Gartland; Niklas R Jørgensen
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.